Tango Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Tango Therapeutics, Inc. filed its annual 10-K report, highlighting positive clinical data for vopimetostat and TNG260, strategic collaborations, and a cash runway into 2028.
NASDAQ
10-K: Tango Therapeutics Reports FY2024 Results, Highlights Clinical Progress and Outlines Future Plans
Tango Therapeutics' 10-K filing summarizes the company's financial results for 2024, highlights clinical progress with TNG462 and TNG260, and outlines strategic plans for advancing its precision oncology pipeline.
NASDAQ
Tango Therapeutics' 2023 annual report highlights progress in its precision oncology pipeline, including clinical trials for multiple drug candidates and ongoing research collaborations.